Results 231 to 240 of about 2,654,095 (300)

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim   +9 more
wiley   +1 more source

Nanoparticles in Antibacterial Therapy: A Systematic Review of Enhanced Efficacy against Intracellular Bacteria. [PDF]

open access: yesACS Omega
Mendez-Pfeiffer P   +6 more
europepmc   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink   +9 more
wiley   +1 more source

Repurposing the Anticancer Drug Cisplatin for Antibacterial Therapy: Evaluating Its Efficacy Against <i>Pseudomonas aeruginosa</i> Infections. [PDF]

open access: yesInfect Drug Resist
Daghistani H   +18 more
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen   +13 more
wiley   +1 more source

Editorial: The gut microbiome's role in gastric cancer: mechanisms and therapies

open access: yesFrontiers in Microbiology
Duygu Ağagündüz   +2 more
doaj   +1 more source

[Antibacterial therapy of pancreonecrosis].

open access: yesKlinichna khirurhiia, 2001
V V, Saenko, S A, Andreeshchev
openaire   +1 more source

Home - About - Disclaimer - Privacy